Fei K - Search Results

1

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.

Cai W, Lin D, Wu C, Li X, Zhao C, Zheng L, Chuai S, Fei K, Zhou C, Hirsch FR. Cai W, et al. Among authors: fei k. J Clin Oncol. 2015 Nov 10;33(32):3701-9. doi: 10.1200/JCO.2014.58.8293. Epub 2015 Sep 28. J Clin Oncol. 2015. PMID: 26416997 Free PMC article.

2

KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.

Cai W, Su C, Li X, Fan L, Zheng L, Fei K, Zhou C. Cai W, et al. Among authors: fei k. Cancer. 2013 Apr 15;119(8):1486-94. doi: 10.1002/cncr.27940. Epub 2013 Feb 1. Cancer. 2013. PMID: 23378251 Free article.

3

ROS1 fusions in Chinese patients with non-small-cell lung cancer.

Cai W, Li X, Su C, Fan L, Zheng L, Fei K, Zhou C, Manegold C, Schmid-Bindert G. Cai W, et al. Among authors: fei k. Ann Oncol. 2013 Jul;24(7):1822-1827. doi: 10.1093/annonc/mdt071. Epub 2013 Mar 20. Ann Oncol. 2013. PMID: 23514723 Free article.

4

MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.

Li B, Ren S, Li X, Wang Y, Garfield D, Zhou S, Chen X, Su C, Chen M, Kuang P, Gao G, He Y, Fan L, Fei K, Zhou C, Schmit-Bindert G. Li B, et al. Among authors: fei k. Lung Cancer. 2014 Feb;83(2):146-53. doi: 10.1016/j.lungcan.2013.11.003. Epub 2013 Nov 13. Lung Cancer. 2014. PMID: 24331411

5

T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.

Li W, Ren S, Li J, Li A, Fan L, Li X, Zhao C, He Y, Gao G, Chen X, Li S, Shi J, Zhou C, Fei K, Schmid-Bindert G. Li W, et al. Among authors: fei k. Lung Cancer. 2014 Jun;84(3):295-300. doi: 10.1016/j.lungcan.2014.03.011. Epub 2014 Mar 15. Lung Cancer. 2014. PMID: 24685306

6

Association of CDC25 phosphatase family polymorphisms with the efficacy/toxicity of platinum-based chemotherapy in Chinese advanced NSCLC patients.

Cai W, Chen C, Li X, Shi J, Sun Q, Liu D, Sun Y, Hou L, Zhao X, Gu S, Wu Q, Chen H, Zhang W, Jin L, Lu D, Fei K, Su B, Qian J. Cai W, et al. Among authors: fei k. Future Oncol. 2014 May;10(7):1175-85. doi: 10.2217/fon.14.25. Future Oncol. 2014. PMID: 24947259

7

EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.

Yang Y, Yang Y, Zhou X, Song X, Liu M, He W, Wang H, Wu C, Fei K, Jiang G. Yang Y, et al. Among authors: fei k. Lung Cancer. 2015 Mar;87(3):272-7. doi: 10.1016/j.lungcan.2014.12.016. Epub 2015 Jan 5. Lung Cancer. 2015. PMID: 25582278

8

WEE1 kinase polymorphism as a predictive biomarker for efficacy of platinum-gemcitabine doublet chemotherapy in advanced non-small cell lung cancer patients.

Liu D, Wu C, Jiao Y, Hou L, Lu D, Zheng H, Chen C, Qian J, Fei K, Su B. Liu D, et al. Among authors: fei k. Sci Rep. 2015 Jun 9;5:11114. doi: 10.1038/srep11114. Sci Rep. 2015. PMID: 26057002 Free PMC article.

9

Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.

Cheng N, Cai W, Ren S, Li X, Wang Q, Pan H, Zhao M, Li J, Zhang Y, Zhao C, Chen X, Fei K, Zhou C, Hirsch FR. Cheng N, et al. Among authors: fei k. Oncotarget. 2015 Sep 15;6(27):23582-93. doi: 10.18632/oncotarget.4361. Oncotarget. 2015. PMID: 26160838 Free PMC article.

10

Air bronchogram: A potential indicator of epidermal growth factor receptor mutation in pulmonary subsolid nodules.

Dai J, Shi J, Soodeen-Lalloo AK, Zhang P, Yang Y, Wu C, Jiang S, Jia X, Fei K, Jiang G. Dai J, et al. Among authors: fei k. Lung Cancer. 2016 Aug;98:22-28. doi: 10.1016/j.lungcan.2016.05.009. Epub 2016 May 13. Lung Cancer. 2016. PMID: 27393502

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

248 results

Search Page

Filters